Resumen
La espectroscopia por resonancia magnética (MRS) es una técnica disponible recientemente en la práctica radiológica que ofrece una valoración bioquímica, metabólica y funcional de los tejidos y complementa de una manera adecuada los estudios imaginológicos convencionales. Su uso se implementa cada día más por los radiólogos, en especial por los neurorradiólogos. La espectroscopia por resonancia magnética (MRS) permite diferenciar de una manera adecuada el cerebro normal de los tejidos anormales. Ha sido utilizada en la valoración de tumores cerebrales, en su documentación y en la caracterización de los cambios metabólicos asociados con el crecimiento tumoral, el grado de malignidad, la respuesta y los efectos secundarios al tratamiento. Su uso se ha extendido actualmente a la valoración de otras patologías como alteraciones metabólicas, estudio de demencias y convulsiones, desórdenes vasculares e infarto cerebral, valoración de algunos trastornos psiquiátricos y mas recientemente en la valoración de patología cardiaca, hígado, mama y de la próstata. En el presente artículo presentamos una revisión práctica de las aplicaciones y conceptos básicos relacionados con la aplicación de la MRS en el estudio de algunas enfermedades del sistema nervioso central (Acta Neurol Colomb 2006;22:42-54).
Citas
Kwock L. Localized MR spectroscopy: basic principles. Neuroimaging Clinics of North America 1998;8:713-732.
Kwock L. Clinical proton magnetic resonance spectroscopy: basic principles. In: Clinical applications of MR spectroscopy. Mukherji SK, ed. Wily-Liss, New York, 1998, pp 1-32.
Salibi N, Brown M. Clinical MR spectroscopy; 1 edition; New York; Wiley-Liss; 1998; 20-24.
Castillo M, Kwock L. Clinical applications of proton MR spectroscopy in the evaluation of common intracranial tumors. Top Magn Reson Imaging. 1999;10:104-113.
Salibi N, Brown M. Clinical MR spectroscopy; 1 edition; New York; Wiley-Liss; 1998; 62-105.
Richards TL, Dager SR, Posse S. Functional MR spectroscopy of the brain. Neuroimaging clinics of North America 1998;8:823-834.
Pfeuffer J, Tkàc I, Provencher SW, Gruetter R. Toward an in vivo neurochemical profile: quantification of 18 metabolites in short echo time 1H NMR spectra of rat brain. J. Magn. Reson 1999;141:104-120.
Castillo M, Kwock L, Mukherji SK. Clinical applications of proton MR spectroscopy. AJNR Am J Neuroradiol 1996;17:1-15.
Govindaraju V, Young K, Maudsley AA. Proton NMR chemical shift and coupling constants for brain metabolites. NMR in Biomed 2000;13:12999-153.
Simmons L, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991;45:37-45.
Brulatout S, Mèric P, Loubinnoux I, et al. A one- dimensional (proton and phosphorus) and two dimensional (proton) in vivo NMR spectroscopic study of reversible global cerebral ischemia. J Neurochem 1996;66:2491-2499.
Tsai G, Coyle JT. N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 1995;46:531-540.
Wittsck HJ, Kugel H, Roth B, Heindel W. Quantitative measurements with localized 1H MR spectroscopy in children with Canavan’s disease. J Magn Reson Imag 1996;6:889-893.
Pouwels PJ, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson. Med 1998;39:53-60.
Wang Y, Li SJ. Differentiation of metabolic concentrations between gray matter and white matter of human brain by in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 1998;39:28-33.
Li BS, Wang H, Gonen O. Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magn Reson Imaging 2003;21:923-928.
Ross BD. Biochemical considerations in 1H spectroscopy. Glutamate and glutamine;myo-inositol and related metabolites. NMR Biomed 1991;4:59-63.
Brand A, Richter-Landsberg C,Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Devl. Neurosci 1993;15:289-298.
Kreis R, Ernst T, Ross B: Development of the human brain: In vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med 1993;30:1-14.
Viola A, Chabrol B, Nicoli F, et al. Magnetic resonance spectroscopy study of glycine pathways in nonketotic hyperglycinemia. Pediatric research 2002;52:292-300.
Gabis L, Parton P, Roche P, et al. In vivo 1H magnetic resonance spectroscopic measurement of brain glycine levels in nonketotic hyperglycinemia. J neuroimaging 2001;11:209-211.
Kinoshita Y, Kajiwara H, Yokota A, Koga Y. Proton magnetic resonance spectroscopy of brain tumors: an in vitro study. Neurosurgery 1994;35:606-613.
Londono A, Castillo M, Armao D, Kwock L, Suzuki K. Unusual MR spectroscopic imaging pattern of an astrocytoma: lack of elevated choline and high myi-inositol and glycine levels. AJNR Am J Neuroradiol 2003;24:942-945.
Sappey-Marinier D, Calabrese G, Fein G, Hugg JW, Biggins C, Weiner MW. Effect of photic stimulation on human visual cortex, lactate and phosphates using 1H and 31P magnetic resonance spectroscopy. J Cereb Blood Flow Metab. 1992;12:584-592.
Posse S, Dager SR, Richards TL, et al. In vivo measurement of regional brain metabolic response to hyperventilation using magnetic resonance: proton echo planar spectroscopic imaging PEPSI. Magn Reson Med 1997;37:858-865.
Salibi N, Brown M. Clinical MR spectroscopy; 1 edition; New York; Wiley-Liss; 1998; 157-163.
Okazaki H. Fundamentals of neuropathology. Morphologic basis of neurologic disease, 2nd ed. Igaku Shoin, New York, 1989, pp203-205.
Earnest F, Kelly PJ, Scheithauer BW, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 1988; 166:823-827.
Nelson SJ, Dr rer Nat, McKnight TR, Henry RG. Characterization of untreated gliomas by magnetic resonance spectroscopic imaging. Neuroimag Clin N Am 2002;12:599-613.
Poptani H, Gupta RK, Roy R, et al. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol 1995;16:1593-1603.
Castillo M, Kwock L. Proton MR spectroscopy of common brain tumors. Neuroimaging Clinics of North America 1998;8:733-752.
McKnight TR, Noworolski SM, Vigneron DB, et al. An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma. J Magn Reson Imaging 2001;13:167-177.
Fountas KN, Kapsalaki EZ, Vogel RL, Fezoulidis L, Robinson JS, Gotsis ED. Noninvasive histologic grading of solid astrocytomas using proton magnetic resonance spectroscopy. Stereotac Funct Neurosurg 2004;82:90-97.
Kwock L, Smith JK, Castillo M, et al. Clinical applications of proton MR spectroscopy in oncology. Technology in cancer research and treatment 2002;1:17-28
Hendrikus G, Krouwer J, Kim TA, et al. Single voxel proton MR spectroscopy of non-neoplastic brain lesion suggestive of a neoplasm. Am J Neuroradiol 1998;19:1695-1703.
Bitsch A, Bruhn H, Vougioukas V, et al. Inflamatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. Am J Neuroradiol 1999;20:1619-1627.
Fulham MJ, Bizzi A, Dietz MJ, et al. Mapping of brain tumor metabolites with proton MR spectroscopy imaging: clinical relevance. Radiology 1992;185:675-686.
Heesters MA, Kaudstaal J, Go KG, et al. Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value. J Neurooncol 1999;44:255-266.
Tien RD, Lai PH, Smith JS, Lazeyras F. Single voxel proton brain spectroscopy exam (PROBE/SV) in patients with primary brain tumors. AJR 1996;167:201-209.
Castillo M, Smith JK, Kwock L. Correlation of Myo0inositol levels and grading of cerebral astocytomas. AJNR Am J Neuroradiol 2000;21:1645-1649.
Uhm JH, Dooley NP, Villemure JG, Yong VW. Glioma invasion in vitro: regu;ation by matrix metalloprotease-2 and protein kinase C. Clin Exp Metastasis 1996;14:421-433.
Ott D, Henning J, Ernst T. Human brain tumors: assessment with in vivo proton MR spectroscopy. Radiology 1993;186:745-752.
Kuesel AC, Donnelly SM, Halliday W,Sutherland GR, Smith IC. Mobile lipids and metabolic heterogeneity of brain tumors as detectable by ex vivo 1H MR spectroscopy. NMR Biomed 1994;7:172-180.
Ishimaru H, Morikawa M, Iwanaga S, et al. Differentiation between high grade glioma and metastasic brain tumor using single voxel proton MR spectroscopy. Eur Radiol 2001;11:1784-1791.
Grand S, Passaro G, Ziegler A, et al. Necrotic tumor versus brain abscess: importance of amino acids detected at H MR spectroscopy initial results. Radiology
;213:785-793.
Pretell EJ, Martinot C, Garcia HH, Alvarado M, Bustos JA, Martinot C. Differential diagnosis between cerebral tuberculosis and neurocysticercosis by magnetic resonance spectroscopy. J comput assist tomogr 2005;29:112-114.
Dooms GC, Hecht S, Brant-Zawadski M, et al. Brain radiation lesions:MR imaging. Radiology 1986;158:149-155.
Holman BL, Abdel-Dayem H. The clinical role of SPECT in patients with brain tumors. Journal of Neuroimaging 1995;5:34-39.
Vertosick FT, Selker RG, Grossman SJ, Joyce JM. Correlation of thallium- 201 photon emission computed tomography and survival after treatment failure in patients with glioblastoma multiforme. Neurosurgery 1994;34:396-401.
Kahn D, Follet KA, Bushnell DL, et al. Diagnosis of recurrent brain tumor: value of 201 TI SPECT vs 18F-fluorodeoxiglucosa PET. AJR 1994;163:1459-1465.
Lee M, Pirzkall A, Akazawa P, Verhey LJ, Melson SJ. MR spectroscopy of radiation effects in healthy brain tissue following radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:S133-134.
Esteve F, Rubin C, Grand S, Koloide H, Le Bas JF. Transient metabolic changes observed with proton MR spectroscopy in normal human brain after radiation therapy. Int J Radiat Oncol Biol Phys 1998;40:279-286.
Rock JP, Hearshen D, Scarpace L,et al. Correlations between magnetic resonance spectroscopy and image-guided histopathology with special attention to radiation necrosis. Neurosurgery 2002;51:912-919.
Dilon W. Assesing the patient with glioma for recurrent disease. American Society of Neuroradiology meeting ASNR 2004:43-49.
Gober JR. Noninvasive tissue characterization of brain tumor and radiation therapy using magnetic resonance spectroscopy. Neuroimaging Clin North Am 1993;3:779-802.
Remy C, Grand S, Lai ES, et al. 1H MRS of human brain abscesses in vivo and in vitro. MRM 1995;34:508-514.
Gupta RK, Poptani H, Kohli A, et al. In vivo localized proton magnetic resonance spectroscopy in intracranial tuberculomas. Indian J med Res 1995;101:19-24.
Arbeláez A, Medina E, Restrepo F, Castillo M.
Cerebral tuberculosis. Semin Roentgenol 2004;39:474-478.
Cecil KM, Lenkinski RE. Proton MR spectroscopy in inflammatory and infectious brain disorders. Neuroimaging Clinics of North America 1998;8:863-880.
Atchen E. Aspects of proton MR spectroscopy in the seizure patient. Neuroimaging Clinics of North America 1998;8:849-862.
Thompson JE, Castillo M, Kwock L, et al. Usefulness of proton MR spectroscopy in the evaluation of temporal lobe epilepsy. AJR 1998;170:771-776.
Hetherington HP, Gadian DG, Ng TC. Magnetic resonance spectroscopy in epilepsy: Technical issues. Epilepsia 2002:43(suppl 1):25-31.
Connelly A, Van Paesschen W, Porter DA,et al. Proton magnetic resonance spectroscopy in MRI-negative temporal lobe epilepsy. Neurology 1998;51:61-6.
Ricci PE. Proton MR spectroscopy in ischemic stroke and other vascular disorders. Neuroimaging clinics of North America 1998;8:881-900.
Stengel A, Neumann-Haefelin T, Singer OC, et al. Multiple spin-echo spectroscopic imaging for rapid quantification assessment of N-Acetylaspartate and lactate in acute stroke. Magnetic Resonance in Medicine 2004;52:228-238.
Huang W, Alexander GE, Chang L, et al. Brain metabolite concentration and dementia severity in Alzheimer’s disease: a (1) H MRS study. Neurology 2001 28;57(4):626-32.
Catani M, Cherubini A,Howard R, et al. (1) H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 2001 8;12(11):2315-7.
Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001 13;56(5):592-8.
Ross BD, Blum S, Cowdan R, et al. In vivo MR spectroscopy of human dementia. Neuroimaging clinics of North America 1998;8:809-822.
Sancora G, Gueorguieva R, Epperson CN, et al. Subtype-specific alterations of gamma-amynobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004;61:705-713.
Dager SR, Friedman SD, Parow A, et al. Brain metabolic alterations in medication free patients with bipolar disorder. Arch Gen Psychiatry 2004;61:450-480.
Mirza Y, Tang J, Russell A, et al. Reduced anterior cingulated cortex glutamatergic concentrations in childhood major depression. J Am Acad Child Adolesc Psychiatry 2004;43:3410348.
Wood SJ, Berger G, Velakoulis D, et al. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high risk individuals. Schizophr Bull 2003;29:831-843.
Smith EA, Russell A, Lorch E, et al. Increased medial thalamic choline found in pediatric patients with obsessive-compulsive disorder versus major depression or healthy control subjects: a magnetic resonance spectroscopy study. Biol Psychiatry 2003;54:1399-1405.
Vythilingam M, Charles HC, Tupler LA, Blitchington T, Kelly L, Krishnan KR. Focal and lateralized subcortical abnormalities in unipolar major depressive disorder: an automated multivoxel proton magnetic resonance spectroscopy study. Biol Psychiatry 2003;54:744-750.
Lyoo IK, Kong SW, Sung SM, et al. Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate. Psychiatry Res 2003;123:87-100.
Chang L, Cloak CC, Ernst T. Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders. J Clin Psychiatry 2003;64 suppl 3:7-14.
Castillo M, Kwock L, Courvosisie HE, et al. Proton MR spectroscopy in psychiatric and neurodevelopment childhood disorders. Neuroimaging Clinics of North America 1998;8:901-912.
Courvoisie H, Hooper SR, Fine C, Kwock L, Castillo M. Neurometabolic functioning and neuropsychological correlates in children with ADHD-H: preliminary findings. J Neuropsychiatry Clin Neurosci 2004;16:63-69.
Hesslinger B, Thiel T, Tebartz van Elst L, Henning J, Ebert D. Attention deficit disorder in adults with or without hyperactivity: Here is the difference? A study in humans using short echo H magnetic resonance spectroscopy. Neuroscience Letter 2001;204:117-119.
MacMaster FP, Carrey N, Sparkes S, Kusumakar V. Proton spectroscopy in medication free pediatric attention deficit hyperactivity disorder. Biol Psychiatry 2003;53:184-187.
Jin Z, Zang YF, Zen YW, Zhang L, Wang YF. Striatal neuronal loss or dysfunction and choline rise in children with attention deficit hyperactivity disorder: a H magnetic resonance spectroscopy study. Neuroscience Letters 2001;315:45-48.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.